# An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis

> **NCT00346294** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 115 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00346294
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2006-03
- **Final completion:** 2006-07
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2020-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00346294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00346294, "An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00346294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*